Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Global prescription orphan drug annual growth in revenues from 2011 to 2024
Annual growth in global revenue for prescribed orphan drugs 2011-2024
This statistic displays the annual growth in worldwide revenues generated by prescribed orphan drugs from 2011 to 2024. During 2018, orphan drugs revenues increased by 11.1 percent. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Global prescription orphan drug annual growth in revenues from 2011 to 2024
Growth per year
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

April 2019

Region

Worldwide

Survey time period

as of April 2019

Supplementary notes

Products that have orphan and non-orphan drug designations and are expected to generate less than 50% of their sales in 2018 and 2024 from their orphan-designated indication/s, are excluded from this analysis. This has led to the exclusion of therapies such as Avastin, Opdivo, Enbrel, Herceptin, Humira and Remicade.
* From 2019 on projected.

Annual growth in global revenue for prescribed orphan drugs 2011-2024
This statistic displays the annual growth in worldwide revenues generated by prescribed orphan drugs from 2011 to 2024. During 2018, orphan drugs revenues increased by 11.1 percent. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Orphan drugs"
  • Market overview
The most important statistics
  • Companies
  • Products
  • Research and development
  • Rare diseases
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.